Diagnose en behandeling van het myelodysplastisch syndroom bij patiënten met een laag en laag-intermediair risico

Myelodysplastic syndromes (MDS) represent a heterogeneous group of bone marrow diseases which are characterized by ineffective hematopoiesis and abnormal cell morphology (dysplasia). The most recent WHO-guidelines classify MDS, myeloproliferative disorders (MPN), MDS/MPN neoplasms, acute myeloid leukemia and myeloid neoplasms associated with eosinophilia as myeloid neoplasms. In the twentieth century, the designation 'pseudo aplastic anemia' referred to the paradoxical combination of cytopenia and an hypercellular bone marrow. Patients with MDS have an increased risk of developing acute leukemia. Until a few years ago the treatment of patients with low or intermediate risk MDS was restricted to supportive care with transfusion and hematopoietic growth factors. New insights in the pathogenesis and successful treatments with immunosuppressive therapy, lenalidomide and hypomethylating agents hold out hope for the future.

Jaar van publicatie:2017